Cellectis Says European Commission Has Granted An Orphan Drug Designation To Its Product Candidate UCART22 For Treatment Of Acute Lymphoblastic Leukemia
Portfolio Pulse from Benzinga Newsdesk
Cellectis announced that the European Commission has granted Orphan Drug Designation to its product candidate UCART22 for the treatment of Acute Lymphoblastic Leukemia. UCART22 is an allogeneic CAR T-cell product targeting CD22, currently in a Phase 1/2 study.
June 04, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellectis has received Orphan Drug Designation from the European Commission for its product candidate UCART22, which is in Phase 1/2 trials for treating Acute Lymphoblastic Leukemia.
The Orphan Drug Designation is a significant regulatory milestone that can provide benefits such as market exclusivity, tax credits, and reduced regulatory fees. This is likely to positively impact Cellectis' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100